Sands Capital Management - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 514 filers reported holding BIO-TECHNE CORP in Q2 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
Sands Capital Management ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q3 2023$648,707
+5.0%
9,530
+26.0%
0.00%0.0%
Q2 2023$617,613
-98.9%
7,566
-99.0%
0.00%
-98.9%
Q1 2023$55,446,193
+90737.3%
747,354
+1.5%
0.18%
-20.8%
Q4 2022$61,039
-99.9%
736,473
+307.5%
0.23%
+19.7%
Q3 2022$51,330,000
-7.0%
180,740
+13.5%
0.19%
+1.0%
Q2 2022$55,201,000
-23.2%
159,247
-4.0%
0.19%
+15.8%
Q1 2022$71,845,000
+42.8%
165,908
+70.7%
0.16%
+77.4%
Q4 2021$50,296,000
+4.7%
97,220
-1.9%
0.09%
+16.2%
Q3 2021$48,047,000
+9.0%
99,153
+1.2%
0.08%
+6.7%
Q2 2021$44,097,000
+32.9%
97,936
+12.7%
0.08%
+17.2%
Q1 2021$33,184,00086,8850.06%
Other shareholders
BIO-TECHNE CORP shareholders Q2 2023
NameSharesValueWeighting ↓
Brown Capital Management 2,119,107$256,179,0003.12%
STONE RUN CAPITAL, LLC 42,925$5,189,0002.67%
440 INVESTMENT GROUP, LLC 27,820$3,363,0002.56%
Summit Creek Advisors LLC 106,517$12,877,0002.54%
MAIRS & POWER INC 1,444,480$174,623,0002.10%
QUANTUM CAPITAL MANAGEMENT 57,094$6,902,0001.63%
Select Equity Group, L.P. 1,709,914$206,711,503,0001.57%
FRIESS ASSOCIATES LLC 144,610$17,482,0001.53%
Tygh Capital Management, Inc. 61,813$7,473,0001.49%
First Light Asset Management, LLC 38,654$4,673,0001.48%
View complete list of BIO-TECHNE CORP shareholders